Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
4/10/2026, 12:00:00 AM
Expected FDA decision date for oral obesity drug orforglipron scheduled. High importance estimated as FDA decisions for major drugs typically cause >10% price swings.
Korean Translation
경구용 비만 치료제 올포글리프론(orforglipron)에 대한 FDA 승인 결정 예정일임. 주요 약물에 대한 FDA 결정은 통상 10% 이상의 주가 변동을 초래하므로 높은 중요도로 예상됨.
Related Recent Events
Alphabet Inc (GOOGL) · Other
Google I/O 2026 developer conference is scheduled for 2026-05-19. Developer conferences usually have a 1-5% price impact. Updates on AI, Gemini, and Android are expected.
5/19/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-11. Analysts forecast revenue between $600M-$625M and adjusted EBITDA of $35M-$55M. Low importance is estimated as the market typically anticipates scheduled earnings results, which is forecasted.
5/11/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
First quarter 2026 earnings results and conference call scheduled.
5/5/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
Q1 2026 earnings release on May 5, 2026, with low importance estimated as the date is unconfirmed, expected.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
First quarter 2026 earnings release; importance is estimated as Medium because quarterly earnings reports often result in price movements exceeding 5%, scheduled.
4/24/2026, 12:00:00 AM